Literature DB >> 10933939

Targeted delivery of plasmid DNA to myogenic cells via transferrin-conjugated peptide nucleic acid.

K W Liang1, E P Hoffman, L Huang.   

Abstract

We describe a novel approach to conjugate a targeting ligand to plasmid DNA without affecting either its supercoiled conformation or its ability to be efficiently transcribed. A 14-mer peptide nucleic acid (PNA) containing lysine and cysteine on each end was designed to target to a unique sequence located at the antibiotic resistance gene of the plasmid. The binding of PNA to the plasmid was found to be dose-dependent and sequence-specific and not to change the conformation of the plasmid. Transferrin (Tf) was conjugated with PNA via a reversible disulfide bond using N-succinimidyl-3-(2-pyridyldithio)propionate. Tf-PNA retained the ability to the plasmid in a sequence-specific manner. The efficiency of this bioconjugate for delivering plasmid was examined in cultured myoblasts and myotubes. Naked DNA and Tf-PNA/DNA showed no transfection activity in either myoblasts or myotubes. Polyethyleneimine (PEI) is required for significant increase of the transfection efficiency. At N:P ratio of 5, Tf-PNA enhanced gene transfection about fourfold over that of the DNA/PEI complex in both myoblasts and myotubes. This enhancement could be inhibited by excess free Tf, indicating that the enhancement of transfection was through Tf-mediated endocytosis. These findings suggest that this targeting system may have the potential for gene transfer to myogenic cells in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10933939     DOI: 10.1006/mthe.2000.0043

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  11 in total

Review 1.  PNA Technology.

Authors:  Peter E Nielsen
Journal:  Mol Biotechnol       Date:  2004-03       Impact factor: 2.695

2.  Temperature-assisted cyclic hybridization (TACH): an improved method for supercoiled DNA hybridization.

Authors:  Iulian I Oprea; Oscar E Simonson; Pedro M D Moreno; Joana R Viola; Karin E Lundin; C I Edvard Smith
Journal:  Mol Biotechnol       Date:  2010-06       Impact factor: 2.695

Review 3.  Intracellular trafficking of nucleic acids.

Authors:  Rui Zhou; R Christopher Geiger; David A Dean
Journal:  Expert Opin Drug Deliv       Date:  2004-11       Impact factor: 6.648

Review 4.  Nuclear entry of nonviral vectors.

Authors:  D A Dean; D D Strong; W E Zimmer
Journal:  Gene Ther       Date:  2005-06       Impact factor: 5.250

Review 5.  Nonviral gene transfer to skeletal, smooth, and cardiac muscle in living animals.

Authors:  David A Dean
Journal:  Am J Physiol Cell Physiol       Date:  2005-08       Impact factor: 4.249

6.  Noncovalent Attachment of Chemical Moieties to siRNAs Using Peptide Nucleic Acid as a Complementary Linker.

Authors:  Wei Jin; Akshay Jain; Hao Liu; Zhen Zhao; Kun Cheng
Journal:  ACS Appl Bio Mater       Date:  2018-08-10

7.  Formulation of a peptide nucleic acid based nucleic acid delivery construct.

Authors:  Peter G Millili; Daniel H Yin; Haihong Fan; Ulhas P Naik; Millicent O Sullivan
Journal:  Bioconjug Chem       Date:  2010-02-04       Impact factor: 4.774

8.  Amphiphilic block copolymers enhance cellular uptake and nuclear entry of polyplex-delivered DNA.

Authors:  Zhihui Yang; Gaurav Sahay; Srikanth Sriadibhatla; Alexander V Kabanov
Journal:  Bioconjug Chem       Date:  2008-08-27       Impact factor: 4.774

9.  Direct application of plasmid DNA containing type I interferon transgenes to vaginal mucosa inhibits HSV-2 mediated mortality.

Authors:  Bobbie Ann Austin; Cassandra M James; Peter Härle; Daniel J J Carr
Journal:  Biol Proced Online       Date:  2006-06-14       Impact factor: 3.244

10.  Peptide-Functionalized Dendrimer Nanocarriers for Targeted Microdystrophin Gene Delivery.

Authors:  Jessica Hersh; José Manuel Condor Capcha; Camila Iansen Irion; Guerline Lambert; Mauricio Noguera; Mohit Singh; Avinash Kaur; Emre Dikici; Joaquín J Jiménez; Lina A Shehadeh; Sylvia Daunert; Sapna K Deo
Journal:  Pharmaceutics       Date:  2021-12-15       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.